The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Tremfya (guselkumab) on September 26, 2025. This approval, designated as BLA 761061 S-29, specifically addresses an efficacy supplement, indicating a formal review and acceptance of new data supporting the drug's effectiveness. The application was submitted by Janssen Biotech.

Background

Guselkumab, known commercially as Tremfya, is an established biologic medication. Supplemental applications to the FDA, particularly those related to efficacy, are submitted when new data becomes available that supports an expansion or modification of a drug's approved uses. These updates can include new indications, new patient populations, or refined dosing regimens based on further clinical evidence. The "Class: Efficacy" designation for this supplemental application confirms that the FDA's review focused on the drug's demonstrated effectiveness for a specific therapeutic purpose.

What this means

This supplemental approval for Tremfya (guselkumab) signifies that the FDA has evaluated and accepted additional clinical evidence demonstrating the drug's efficacy. While the specific details of the new or expanded efficacy claim are not provided in the summary data, such approvals are crucial for broadening the therapeutic scope of existing medications. For clinicians, this means Tremfya may now be considered for a wider range of patients or conditions, or its use in an existing indication may be further supported by new data. Patient advocates and researchers will find this update important as it reflects ongoing development and refinement of treatment options, potentially impacting clinical practice guidelines and future research directions for conditions treated by guselkumab.

Source

The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval was granted on September 26, 2025, and details are publicly accessible on the accessdata.fda.gov website under application number BLA 761061, specifically supplemental application S-29.